A negative model finding does not establish that benzodiazepine withdrawal cannot occur.
The retrospective study examined 407 ventilated children and repeated withdrawal-assessment scores during opioid weaning. Greater cumulative opioid exposure and recent opioid reductions were associated with the defined withdrawal endpoint. The model did not establish associations for cumulative intravenous benzodiazepine exposure or its dose decrease.
The endpoint was measured during an opioid-weaning context with overlapping medicines and illness. Exposure windows and assessment sensitivity can influence which relationships are detectable. Observational modeling cannot establish a universally safe reduction threshold.
Keep the negative benzodiazepine result tied to this design. It cannot exclude withdrawal in a particular child or identify the cause of every elevated score. Review all medication changes, symptoms, timing and competing clinical explanations instead of equating a nonsignificant coefficient with biological impossibility.
Source: PMC12991735, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: A Synthetic Cannabinoid Enhanced Clonazepam but Not Clobazam in One Mouse Seizure Model.